Technology
Health
Biotechnology

Verastem

$1.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-5.00%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Verastem and other stocks, options, ETFs, and crypto commission-free!

About VSTM

Verastem, Inc. Common Stock, also called Verastem, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Read More It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

CEO
Employees
169
Headquarters
Needham, Massachusetts
Founded
2010
Market Cap
103.43M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.13M
High Today
$1.44
Low Today
$1.31
Open Price
$1.40
Volume
1.12M
52 Week High
$10.35
52 Week Low
$1.16

Collections

Technology
Health
Biotechnology
Cancer Prevention
Biopharmaceutical
Medical
Pharmaceutical
US

VSTM News

Yahoo FinanceJun 24

Verastem Up on Positive Data From Early-Stage Copiktra Study

4,136

VSTM Earnings

-$0.53
-$0.45
-$0.37
-$0.29
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

Popular Stocks

More VSTM News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.